Company intelligence
PeptiMatrix
Next generation peptide hydrogels for 3D cell culture
About PeptiMatrix
PeptiMatrix is a UK based biotech company providing researchers with fully synthetic, animal free peptide hydrogels for advanced 3D cell culture. Traditional animal derived matrices limit progress through batch variability, poor scalability, and ethical concerns. Our peptide hydrogels remove these barriers with a clean, chemically defined, and highly tunable platform that supports reliable and reproducible research. PeptiMatrix is used across oncology, organoid development, and organ on chip technologies, helping researchers build more predictive and human relevant in vitro models. By providing a consistent and controllable environment for cells, our hydrogels enable higher quality data and more robust biological insights. We work with academic groups, biotech innovators, and industry partners who are driving the next generation of in vitro science, and we are committed to supporting the global shift toward ethical, reproducible, and scalable research systems.
Verified activity
Signals from PeptiMatrix
2 published signals
Research & Knowledge
PeptiMatrix features as part of the work in the new National Centre for the Replacement, Refinement and Reduction of Animals in Research Impact Report, highlighting its collaboration with Dr Mattéa Finelli at the University of Nottingham, STRATASTEM LIMITED, and Dr Richard Elsworthy at the University of Birmingham.
Reported by PeptiMatrix
Presence & Recognition
PeptiMatrix CEO John Curd explored the topic of fully defined, animal-free matrices in the Physicians Committee for Responsible Medicine / NURA training webinar.
Reported by PeptiMatrix